E-DRUG" Report: EU-ANDEAN Trade Agreement impact on Access to Medicines in Peru
---------------------------------------------------------------------
A prospective impact study
This study, carried out by the IFARMA foundation in Colombia, was
commissioned by the EU-CAN Alliance for Access to Medicines and has now
been published by HAI Europe. The study evaluates the potential impact
on access to medicines in Peru from the intellectual property measures
proposed by the European Union as part of the trade agreement being
negotiated between the EU and some Andean countries. It specifically
assesses the impact of increasing the effective duration of
pharmaceutical patents and test data protection, as proposed by the EU
in February 2009.
The analysis of the impact is based on the 'Guide to estimating the
impact on access to medicines due to changes in intellectual property
rights', produced jointly by the World Health Organization (WHO) and the
Pan-American Health Organisation (PAHO). The guide outlines the
Intellectual property rights impact assessment (IPRIA) model.
In the meantime, the most problematic provisions have been taken out of
the agreement. However, this study has served as a useful advocacy tool
and will be an important reference document for negotiations toward
other EU trade agreements, giving insight to EU external policy on
Intellectual Property and its impact on Access to Medicines.
To download, please click on this link
[http://www.haiweb.org/11112009/ReportIFARMAImpactStudyPeru(EN).pdf\]
For the report in Spanish, please click on this link
[http://www.haiweb.org/11112009/ReportIFARMAImpactStudyPeru(ES).pdf\]
For questions regarding the methodology or other studies, please contact
Miguel Cortes [miguelcortes33@gmail.com] or Sophie Bloemen
[sophie@haiweb.org].
The Colombian impact study will also be published shortly in English.
Health Action International
Email: sophie@haiweb.org
Website: http://www.haiweb.org/>
"Terri - Louise Beswick" <Terri@haiweb.org>